<DOC>
	<DOCNO>NCT02843659</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy treatment either lulizumab BMS-986142 versus placebo subject moderate severe primary Sjögren 's syndrome measure change baseline ESSDAI Week 12 active treatment arm ( lulizumab BMS-986142 , respectively ) placebo arm .</brief_summary>
	<brief_title>Proof Concept Study Evaluate Efficacy Safety BMS-931699 ( Lulizumab ) BMS-986142 Primary Sjögren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Subjects diagnose classified moderate severe primary Sjögren 's Syndrome base 2016 ACREULAR Sjögren 's Syndrome Classification Criteria least 16 week prior screen ESSDAI ≥ 5 include disease activity ( score &gt; 0 ) least one follow domain : Glandular , Articular , Hematological , Biological , Lymphadenopathy Positive antiSSA/Ro and/or antiSSB/La autoantibody Unstimulated whole saliva secretion &gt; 0.01 ml/min Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug must pregnant breastfeeding . Male female subject must willing adhere protocolmandated highly effective contraception duration study protocolspecified follow period . Hormonebased contraceptive method permit Secondary Sjögren 's syndrome presence systemic autoimmune disease ( eg , RA , SLE , multiple sclerosis , vasculitis ) Very severe primary Sjögren 's syndrome severe complication primary Sjögren 's syndrome time screen visit Active systemic latent bacterial ( include tuberculosis ) , viral fungal infection , evidence current chronic Hepatitis B C infection , HIV infection Any significant concurrent medical condition time screen baseline visit Use methotrexate , cyclophosphamide , cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil ( MMF ) leflunomide within 12 week screen visit Previous treatment biologics therapy either market development within 6 month prior screen visit Treatment start unstable dose hydroxychloroquine within 8 week screen visit Oral corticosteroid &gt; 10 mg/day within 14 day dose ( Day 1 ) , corticosteroid therapy ≥ 1 mg/kg 4 week precede enrollment , intravenous , intramuscular intraarticular corticosteroid within 4 week screen visit Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>